Human Antibody-Producing Rodents

Multiple innovative platforms are currently available for antibody discovery using genetically modified mice that express fully-human heavy and light chain variable regions.  These animals can generate diverse repertoires of in vivo affinity-matured antibodies with intrinsic drug-like properties necessary for successful development, including high potency, specificity, solubility, and manufacturability.  A key advantage is that in having full-human variable regions, the antibodies have low risk of immunogenicity, thus mitigating efficacy-killing anti-drug responses when reformatted as therapeutics.

View LakePharma’s Infographic on Rodent Selection by clicking the image to the left.

Ligand OmniMouse® Harbour H2L2 MouseTM Trianni Mouse® Alloy GX MouseTM Ablexis AlivaMab Mouse®
Light Chain Hu κ
Hu λ
Hu κ Hu κ
Hu λ
Hu κ
Hu λ
Hu κ     Hu κ     Hu λ
Hu λ
Heavy Chain
Fc
Rat
IgG1
IgG2b
IgG2c
Rat
IgG1
IgG2b
IgG2c
Mouse
IgG1
IgG2b
IgG2c
IgG3
Not disclosed Mouse
IgG
Heavy Chain Repertoire
(no. V Gene Segments)
44 18 44 40+ Not disclosed
Light Chain Repertoire
(no. V Gene Segments)
20 κ
15 λ
11 κ 39 κ
38 λ
19+ κ
22+ λ
Not disclosed
Parental Strain(s) C57Bl/6
SJL
C57Bl/6
FVB
129
C57Bl/6 C57Bl/6
BALB/c
Not disclosed
MHC Haplotype(s) H-2b
H-2s
H-2b
H-2q
H-2b H-2b
H-2d
Not disclosed

References
Lowitz J, Lin G, Somera J, Santibanez-Vargas L, Vo C, Rodriguez E, Nguyen B, Trang M, Nichols J, Kenney J. Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms. Poster presented at PEGS; 2019 Apr. 8-12; Boston, MA.

Maximizing the AlivaMab Mouse Advantage. Retrieved from https://alivamab.com/alivamab-mouse.